Skip to main content

Table 1 Demographic, clinical and laboratory characteristics of the 59 patients with RA

From: Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan

Age, yrs 72 (65–77)
Male, n 16 (27.1)
Disease duration, months 54 (14–186)
csDMARDs use, n 48 (81.4)
MTX use, n 26 (44.1)
Corticosteroid use, n 33 (55.9)
Previous use of bDMARDs 22 (37.3)
Oral bisphosphonate use 21 (35.6)
Positive RF, n 46 (78.0)
Positive ACPA, n 52 (88.1)
Tender joint counts (28), n 5 (3–10)
Swollen joint counts (28), n 5 (2–10)
PtGA, mm 40 (20–70)
EGA, mm 40 (30–53)
CRP, mg/dl 0.64 (0.12–2.14)
MMP-3, ng/ml 124 (66–288)
DAS28-CRP 4.20 (3.39–5.01)
SDAI 20.7 (13.7–30.7)
Total GS score 14 (7–22)
Total PD score 7 (4–15)
  1. The data are median (interquartile range, Q1–4–Q3/4) or number (percentage). ACPA Anti-cyclic citrullinated peptide antibody, bDMARDs biologic disease-modifying antirheumatic drugs, CRP C-reactive protein, DAS Disease Activity Score, csDMARDs Conventional synthetic disease-modifying antirheumatic drugs, EGA Evaluator’s global assessment, ESR Erythrocyte sedimentation rate, GS Gray-scale, MTX Methotrexate, PD Power Doppler, PtGA Patient’s global assessment, RA Rheumatoid arthritis, RF Rheumatoid factor, SDAI Simplified Disease Activity Index